GLRB: IHC Expression in Cancer and Radioligand Target Profile
GLRB, glycine receptor beta, is a cell-surface protein (membrane receptor). In Human Protein Atlas immunohistochemistry, GLRB staining is highest in glioma (100% of samples positive), head and neck cancer (50% of samples positive) and prostate cancer (29% of samples positive). Evidence on whether GLRB internalizes is mixed. Clinical status: FDA-approved drug (any modality).
Is GLRB the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.
Analyze GLRB freeIs GLRB a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ✅ Tumor expression: High IHC staining in glioma, 100% of samples positive.
- ⚠️ Internalization: Mixed evidence.
- ✅ Clinical precedent: FDA-approved drug (any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
GLRB IHC staining by cancer type
Protein expression of GLRB across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Glioma | 0.83 | High | 100% |
| Head and Neck Cancer | 0.25 | Medium | 50% |
| Prostate Cancer | 0.10 | Low | 29% |
| Thyroid Cancer | 0.08 | Low | 25% |
| Cervical Cancer | 0.06 | Low | 9% |
| Skin Cancer | 0.06 | Low | 17% |
| Testicular Cancer | 0.06 | Low | 8% |
| Colorectal Cancer | 0.04 | Low | 11% |
| Breast Cancer | 0.03 | Low | 10% |
| Ovarian Cancer | 0.03 | Low | 9% |
| Bladder Cancer | 0.03 | Low | 9% |
Not detected by IHC in: lymphoma, melanoma, kidney cancer, neuroendocrine tumors, lung cancer, pancreatic cancer, gastric cancer, endometrial cancer, liver cancer.
Is GLRB internalized?
Uncertain. Insufficient literature found.
Sources: PMID 30186111. AI-extracted from abstracts, so verify before citing.
GLRB clinical trials
FDA-approved drug (any modality). Nuclens hasn't indexed trials for GLRB yet. Search ClinicalTrials.gov for GLRB trials.
GLRB normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See GLRB in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
GLRB gene essentiality (DepMap)
CRISPR knockout effect across 1258 cancer cell lines: -0.01 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related glioma radioligand targets
EGFR · HER3 (ERBB3) · c-MET (MET) · ITGAV · B7-H3 (CD276) · SSTR2 · STEAP2 · TMEFF2
See all radioligand therapy targets in glioma.
See how GLRB ranks against 15,000 targets for your indication.
Analyze GLRB freeData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.